Skip to main content
. Author manuscript; available in PMC: 2013 Apr 22.
Published in final edited form as: Curr Opin Clin Nutr Metab Care. 2011 Jul;14(4):402–412. doi: 10.1097/MCO.0b013e3283479109

Table 1.

Summary of the recent epidemiological studies examining the association between sleep duration and obesity in adults

Author Description Cohort Sleep assessment Results
Buxton and Marcelli [16] Cross-sectional
Data source: 2004–05 US National Health Interview Survey (US)
56 507 M, F
Age 18–85 years
Self-reported sleep duration <7 h 6% higher probability of obesity
7–8–h reference category
>8 h 3% higher probability of obesity
Magee et al. [17] Cross-sectional
Data source: 45 and UP Study data (Australia)
45 325 M, F
Age 55–95 years
Self-reported sleep duration Age 55–64 years
    <6 h AOR obesity 1.52 (CI 1.21–1.89; P < 0.001)
    6 h AOR obesity 1.42 (CI 1.26–1.61; P < 0.001)
    7 h reference category
    ≥9 h AOR obesity 1.19 (CI 1.06–1.34; P < 0.001)
Age >65: NS
Magee et al. [18] Cross-sectional
Data source: 45 and UP Study (Australia)
16 951 M, F full-time workers
Age 45–65 years
Self-reported sleep duration Inverse association between sleep duration and BMI (β = –0.615, P < 0.001)
Anic et al. [19] Cross-sectional
Data source: Collaborative Breast Cancer Study (US)
5549 F
Age 20–75 years
Self-reported sleep duration <6 h AOR of obesity 1.89 (CI 1.45–2.47; P < 0.0001); AOR extreme obesity 3.12 (CI 1.70–5.75; P = 0.0003)
6–6.9 h AOR obesity 1.52 (CI 1.23–1.89; P = 0.0003); AOR extreme obesity 2.22 (CI 1.27–3.87; P = 0.0003)
7–7.9 h reference category
≥9 h AOR obesity NS; AOR extreme obesity 2.53 (CI 1.10–5.78; P = 0.023)
Theorell-Haglow et al. [20] Cross-sectional
Data source: Sleep and Health in Women Study (Sweden)
400 F
Age 29–70 years
PSG recorded sleep duration Inverse association between sleep duration and both waist circumference (Adj. β = –1.22 cm/h; P = 0.016) and sagittal abdominal diameter (Adj. β = –0.46cm/h; P = 0.001).
Watanabe et al. [21] Prospective 1 year
Data source: workers of electric power company (Japan)
31 477 M (mean age 40 ± 9 year old) and 3770 F (mean age 38 ± 9 years) Self-reported sleep duration M
    <5 h AOR of obesity 1.91 (CI 1.36–2.67; P < 0.001)
    5–5.9 h AOR of obesity 1.5 (CI 1.25–1.8; P < 0.001)
    7–8 h reference category
F: NS
Bo et al. [22] Prospective 6 years (Italy) 1597 M, F
Age 45–64 years
Self-reported sleep duration Each hour increase in total sleep time = 30% reduction in incident obesity (AOR 0.7/h; CI 0.57–0.86; P < 0.001)
Nishiura and Hashimoto [23] Prospective 4 years
Annual health screen at a gas company (Japan)
2362 M
Age 40–59 years
Self-reported sleep duration <6 h AOR of obesity 2.46 (CI 1.41–4.31; P = 0.011)
7–7.9 h reference category
≥8 h NS
Hairston et al. [24] Prospective 5 years
Three communities from the IRAS Family Study (USA)
322 M, F African–Americans and 775 M, F Hispanic Americans
Age 18–81 years
Self-reported sleep duration Age <40 years
    ≤5 h increase in BMI (+1.8 kg/m2, P < 0.001), SAT (+41 cm2, P < 0.0001), and VAT (+13cm2, P < 0.01)
    6–7 h reference category
    ≥8 h increase in BMI (+0.8 kg/m2, P < 0.001), SAT (+20 cm2, P < 0.01), and VAT (+6 cm2, P < 0.05)
Age >40: NS
Hayes et al. [25] Cross-sectional study
Data source: Cleveland Family Study (USA)
561 M, F
Mean age 44.5 ± 16.1 years
PSG recorded sleep duration Each hour decrease in total sleep time:
    6% increase in leptin levels (P = 0.01)
    14% increase in visfatin levels (P = 0.02)
Each hour decrease in REM sleep:
    15% increase in leptin levels (P = 0.01)
    31% increase in visfatin levels (P = 0.05)

In each study, the association is expressed as higher probability or adjusted odds ratio (AOR) of obesity (BMI ≥30kg/m2) or increased waist circumference. Studies were conducted in different geographical regions. Sleep duration was self-reported or measured by overnight polysomnography (PSG). Adj. β, adjusted beta coefficient; CI, confidence interval; F, female; IRAS, Insulin Resistance Atherosclerosis Study; M, male; NS, not significant; REM, rapid eye movement; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.